{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:33:32Z","timestamp":1775093612436,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,30]]},"DOI":"10.7759\/cureus.76603","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T08:42:35Z","timestamp":1735548155000},"source":"Crossref","is-referenced-by-count":1,"title":["Valproate-Induced Hyperammonemic Encephalopathy Successfully Treated With Levocarnitine in an Elderly Patient Without Liver Dysfunction"],"prefix":"10.7759","author":[{"given":"Masahiko","family":"Kaneko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisaharu","family":"Shikata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisafumi","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1982.00510210061016","article-title":"Asymptomatic hyperammonemia in patients receiving valproic acid","volume":"39","author":"Murphy JV","year":"1982","unstructured":"Murphy JV, Marquardt K. Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol. 1982, 39:591-2. 10.1001\/archneur.1982.00510210061016","journal-title":"Arch Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/15563650902752376","article-title":"Carnitine in the treatment of valproic acid-induced toxicity","volume":"47","author":"Lheureux PE","year":"2009","unstructured":"Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila). 2009, 47:101-11. 10.1080\/15563650902752376","journal-title":"Clin Toxicol (Phila)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/1817-1745.123697","article-title":"Unusual cause of hyperammonemia in two cases with short-term and long-term valproate therapy successfully treated by single dose carglumic acid","volume":"8","author":"Kasapkara CS","year":"2013","unstructured":"Kasapkara CS, Kan\u011f\u0131n M, Ta\u015f FF, Top\u00e7u Y, Demir R, Ozbek MN. Unusual cause of hyperammonemia in two cases with short-term and long-term valproate therapy successfully treated by single dose carglumic acid. J Pediatr Neurosci. 2013, 8:250-2. 10.4103\/1817-1745.123697","journal-title":"J Pediatr Neurosci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.694362","article-title":"Valproate-induced hyperammonemic encephalopathy: a brief review","volume":"28","author":"Lewis C","year":"2012","unstructured":"Lewis C, Deshpande A, Tesar GE, Dale R. Valproate-induced hyperammonemic encephalopathy: a brief review. Curr Med Res Opin. 2012, 28:1039-42. 10.1185\/03007995.2012.694362","journal-title":"Curr Med Res Opin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0087-0","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)\u2014part 1: pharmacokinetic and pharmacodynamic interactions between AEDs","volume":"52","author":"Patsalos PN","year":"2013","unstructured":"Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)\u2014part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013, 52:927-66. 10.1007\/s40262-013-0087-0","journal-title":"Clin Pharmacokinet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2012.04.001","article-title":"Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients","volume":"101","author":"Yamamoto Y","year":"2012","unstructured":"Yamamoto Y, Takahashi Y, Suzuki E, et al.. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients. Epilepsy Res. 2012, 101:202-9. 10.1016\/j.eplepsyres.2012.04.001","journal-title":"Epilepsy Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/cc3742","article-title":"Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?","volume":"9","author":"Lheureux PE","year":"2005","unstructured":"Lheureux PE, Penaloza A, Zahir S, Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?. Crit Care. 2005, 9:431-40. 10.1186\/cc3742","journal-title":"Crit Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2011.12.009","article-title":"Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management","volume":"34","author":"Chopra A","year":"2012","unstructured":"Chopra A, Kolla BP, Mansukhani MP, Netzel P, Frye MA. Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management. Gen Hosp Psychiatry. 2012, 34:290-8. 10.1016\/j.genhosppsych.2011.12.009","journal-title":"Gen Hosp Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.41.9.1444","article-title":"Alteration of renal carnitine metabolism by anticonvulsant treatment","volume":"41","author":"Cami\u00f1a MF","year":"1991","unstructured":"Cami\u00f1a MF, Rozas I, Castro-Gago M, Paz JM, Alonso C, Rodriguez-Segade S. Alteration of renal carnitine metabolism by anticonvulsant treatment. Neurology. 1991, 41:1444-8. 10.1212\/wnl.41.9.1444","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12125","article-title":"Risk factors for hyperammonemia in pediatric patients with epilepsy","volume":"54","author":"Yamamoto Y","year":"2013","unstructured":"Yamamoto Y, Takahashi Y, Imai K, et al.. Risk factors for hyperammonemia in pediatric patients with epilepsy. Epilepsia. 2013, 54:983-9. 10.1111\/epi.12125","journal-title":"Epilepsia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5692\/clinicalneurol.cn-001254","article-title":"Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy. (Article in Japanese)","volume":"59","author":"Yamada H","year":"2019","unstructured":"Yamada H, Shishido T, Mukai T, Araki M, Naka H, Tokinobu H. Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy. (Article in Japanese). Rinsho Shinkeigaku. 2019, 59:258-63. 10.5692\/clinicalneurol.cn-001254","journal-title":"Rinsho Shinkeigaku"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02550.x","article-title":"Noncirrhotic hyperammonaemic encephalopathy","volume":"31","author":"Laish I","year":"2011","unstructured":"Laish I, Ben Ari Z. Noncirrhotic hyperammonaemic encephalopathy. Liver Int. 2011, 31:1259-70. 10.1111\/j.1478-3231.2011.02550.x","journal-title":"Liver Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2017.02.003","article-title":"Valproate-induced hyperammonemic encephalopathy in general hospital patients with one or more psychiatric disorders","volume":"58","author":"Lewis C","year":"2017","unstructured":"Lewis C, Tesar GE, Dale R. Valproate-induced hyperammonemic encephalopathy in general hospital patients with one or more psychiatric disorders. Psychosomatics. 2017, 58:415-20. 10.1016\/j.psym.2017.02.003","journal-title":"Psychosomatics"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13049","article-title":"Risk factors for valproic acid-induced hyperammonaemia in Chinese paediatric patients with epilepsy","volume":"123","author":"Zhu X","year":"2018","unstructured":"Zhu X, Li X, Zhang T, Zhao L. Risk factors for valproic acid-induced hyperammonaemia in Chinese paediatric patients with epilepsy. Basic Clin Pharmacol Toxicol. 2018, 123:628-34. 10.1111\/bcpt.13049","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-011-1838-5","article-title":"Hyperammonemia in review: pathophysiology, diagnosis, and treatment","volume":"27","author":"Auron A","year":"2012","unstructured":"Auron A, Brophy PD. Hyperammonemia in review: pathophysiology, diagnosis, and treatment. Pediatr Nephrol. 2012, 27:207-22. 10.1007\/s00467-011-1838-5","journal-title":"Pediatr Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1023\/a:1021918104127","article-title":"Valproate-induced hyperammonemic encephalopathy","volume":"17","author":"Verrotti A","year":"2002","unstructured":"Verrotti A, Trotta D, Morgese G, Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis. 2002, 17:367-73. 10.1023\/a:1021918104127","journal-title":"Metab Brain Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2007.02.013","article-title":"Different clinical manifestations of hyperammonemic encephalopathy","volume":"10","author":"Gomceli YB","year":"2007","unstructured":"Gomceli YB, Kutlu G, Cavdar L, Sanivar F, Inan LE. Different clinical manifestations of hyperammonemic encephalopathy. Epilepsy Behav. 2007, 10:583-7. 10.1016\/j.yebeh.2007.02.013","journal-title":"Epilepsy Behav"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2020.09.027","article-title":"Incidence, presentation, and risk factors for sodium valproate-associated hyperammonemia in neurosurgical patients: a prospective, observational study","volume":"144","author":"Woo PY","year":"2020","unstructured":"Woo PY, Woo AW, Lam SW, et al.. Incidence, presentation, and risk factors for sodium valproate-associated hyperammonemia in neurosurgical patients: a prospective, observational study. World Neurosurg. 2020, 144:e597-604. 10.1016\/j.wneu.2020.09.027","journal-title":"World Neurosurg"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2018.03.073","article-title":"Valproic acid-induced hyperammonemia: incidence, clinical significance, and treatment management","volume":"8","author":"Baddour E","year":"2018","unstructured":"Baddour E, Tewksbury A, Stauner N. Valproic acid-induced hyperammonemia: incidence, clinical significance, and treatment management. Ment Health Clin. 2018, 8:73-7. 10.9740\/mhc.2018.03.073","journal-title":"Ment Health Clin"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3109\/15563650.2015.1035441","article-title":"Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup","volume":"53","author":"Ghannoum M","year":"2015","unstructured":"Ghannoum M, Lalibert\u00e9 M, Nolin TD, MacTier R, Lavergne V, Hoffman RS, Gosselin S. Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2015, 53:454-65. 10.3109\/15563650.2015.1035441","journal-title":"Clin Toxicol (Phila)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/327474-valproate-induced-hyperammonemic-encephalopathy-successfully-treated-with-levocarnitine-in-an-elderly-patient-without-liver-dysfunction","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T08:42:36Z","timestamp":1735548156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/327474-valproate-induced-hyperammonemic-encephalopathy-successfully-treated-with-levocarnitine-in-an-elderly-patient-without-liver-dysfunction"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.76603","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,30]]}}}